All In Biotech

Drug Trial Radar · NCT07838194

Clinical Trial of NXT007 for the Prophylactic Treatment of Hemophilia A in Infants and Children

A Multicenter, Open-Label, Single-Arm, Phase III Clinical Trial to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of NXT007 Prophylaxis in Pediatric Patients With Hemophilia A

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

50

Planned (sponsor's estimate)

Start

Nov 30, 2026

Primary completion

Sep 30, 2028

Study completion Sep 30, 2031

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
Collaborators
Chugai Pharmaceutical
First posted
Sep 24, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 0 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of NXT007 prophylaxis in pediatric patients aged 0 to 11 years with severe or moderate congenital hemophilia A without factor VIII inhibitors or congenital hemophilia A of any severity (severe, moderate, and mild) with inhibitors (emicizumab-naïve and treated). Patients with hemophilia A aged ≥12 to \<18 years old with a body weight of \<40 kilograms (kg) are also able to participate.

Conditions

  • Hemophilia A

Interventions

  • NXT007Drug

    NXT007 will be administered subcutaneously (SC) according to the schedule in the protocol.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Annualized Bleed Rate (ABR) for Treated Bleeds Over the Main Study Treatment PeriodTime frame: From Month 2 until the clinical cutoff date (at least 7 months of study treatment)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • St. Marianna University Hospital

    Kawasaki-Shi, Kanagawa, Japan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.